Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 36-month results from first-in-human study with shape-changing IOL
➤ New data for recently approved EDOF IOL
➤ Company completes first-in-human robotic cataract surgery
➤ Phase 2 study approved for secondary IOL intended for low-vision patients
➤ Investigational device measures real-time intraoperative aqueous outflow
➤ FDA expands dosing on label for faricimab
➤ Company news
➤ ASCRS news and events
➤ First patients dosed in Phase 3 program evaluating sustained drug delivery for DME
➤ FDA accepts supplemental NDA for presbyopia treatment
➤ FDA grants IND to ocular inflammation, pain treatment for potential expanded indication
➤ Enrollment complete in Phase 3 trial evaluating retinitis pigmentosa therapy
➤ ASCRS news and events
➤ First patient treated with novel crosslinking approach for refractive error
➤ Multisociety working group established to set guidelines for modern IOL classification
➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial
➤ ASCRS news and events
➤ New drop for temporary presbyopia relief approved
➤ First-in-human results for accommodating IOL
➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy
➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response
➤ First patient receives investigational surgical system for glaucoma
➤ Clinical program for RP gene therapy begins
➤ FDA approves IND for steroid-free, topical anti-inflammatory
➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
Nailing outcomes with presbyopia-correcting IOLs is important for many reasons—one of them being patient expectations, as they are paying out of pocket for an advanced-technology lens. But even when you’ve had an excellent surgery, postop complaints can trickle in, and the possible causes for the dissatisfaction are diverse.
Dysfunctional lens syndrome has evolved from a theoretical framework to a clinically validated tool that’s reshaping patient education and surgical decision making. The dysfunctional lens staging system now plays a role in identifying the right intervention at the right time, particularly in the growing field of custom lens replacement.
➤ 510(k) clearance granted to auto kerato-refracto tonometer
➤ First patient dosed with gene therapy for Best disease
➤ Long-term data shows therapy delays geographic atrophy progression
➤ Lead gene therapy candidate to treat wet AMD and DME announced
➤ FDA accepts BLA resubmission
➤ Company news
➤ ASCRS news and events
